POZEN Inc. (POZN) Q2 2012 Earnings Call August 1, 2012; 11:00 am ET Executives Dr. John Plachetka - Chairman, President & Chief Executive Officer Bill Hodges - Chief Financial Officer, Senior Vice President of Finance & Administration Liz Cermak - Executive Vice President & Chief Commercial Officer Stephanie Bonestell - Investor Relations Analysts Michael Tong - Wells Fargo Securities Ken Trbovich - C.K. Cooper Bert Hazlett - Roth Capital Partners Eun Yang - Jefferies & Co. Jason Napodano - Zacks Equity PresentationOperator
Greetings and welcome to POZEN’s second quarter 2012 earnings conference call. At this time all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. (Operator Instructions). It is now my pleasure to introduce your host, Stephanie Bonestell with Investor Relations. Thank you. Ms. Bonestell, you may begin. Stephanie Bonestell Thank you Melissa and good morning everyone. On behalf of POZEN I would like to welcome you to today’s second quarter results conference call. By now you should have received a copy of the company’s press release. If you do not have it, you can access it on the homepage of our website at www.pozen.com, where you can also access a replay of this conference call. Before we begin, I need to remind you that various remarks that we may make about future expectations, plans and prospects for the company, constitute forward-looking statements for the purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995. Such statements include any forecasts or assumptions about potential size or market opportunity, any observations that we may make about the expected timing and amounts of royalty payments from AstraZeneca and other revenue expected from our collaboration partners; the prospects for approval or timing of approval of any of our drug candidates or the way in which the FDA may consider our new drug applications or any particular clinical trial results; results relating to any pending litigation, future clinical trial plans and the likelihood of results of any future trial and our potential commercialization plans, including potential sales and revenue forecasts for our product candidates.